NAT2 polymorphism and lung cancer risk: A meta-analysis

Lung Cancer

Volumn 73, Issue 2, 2011, Pages 153-157

  Cui, Dan ^a,b   Wang, Zhanwei ^c   Zhao, Erjiang ^a,b   Ma, Jie ^d   Lu, Weiquan ^b  

^a ZHENGZHOU UNIVERSITY   (China)

^b Henan Tumor Institute   (China)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^d Henan Tumor Hospital   (China)

Author keywords

Lung cancer; Meta analysis; NAT2; Polymorphism

Indexed keywords

ACYLTRANSFERASE;

ACETYLATION; ARTICLE; CANCER RISK; ETHNICITY; HUMAN; LUNG CANCER; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; SEX;

ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; ODDS RATIO; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 79960043074     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.12.012     Document Type: Article

References (32)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
3. Caporaso N., Goldstein A. Cancer genes: single and susceptibility: exposing the difference. Pharmacogenetics 1995, 5:59-63.
4. Smith C.A., Smith G., Wolf C.R. Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer 1994, 30A:1921-1935.
5. Hein D.W. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 1988, 948:37-66.
6. Wikman H., Thiel S., Jager B., Schmezer P., Spiegelhalder B., Edler L., et al. Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. Pharmacogenetics 2001, 11:157-168.
7. http://www.louisville.edu/medschool/pharmacology/NAT.html.
8. Martinez C., Agundez J.A., Olivera M., Martin R., Ladero J.M., Benitez J. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 1995, 5:207-214.
9. Cascorbi I., Brockmoller J., Mrozikiewicz P.M., Bauer S., Loddenkemper R., Roots I. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res 1996, 56:3961-3966.
10. Oyama T., Kawamoto T., Mizoue T., Yasumoto K., Kodama Y., Mitsudomi T. N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation. Anticancer Res 1997, 17:577-581.
11. Bouchardy C., Mitrunen K., Wikman H., Husgafvel-Pursiainen K., Dayer P., Benhamou S., et al. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics 1998, 8:291-298.
12. Nyberg F., Hou S.M., Hemminki K., Lambert B., Pershagen G. Glutathione S-transferase mu1 and N-acetyltransferase 2 genetic polymorphisms and exposure to tobacco smoke in nonsmoking and smoking lung cancer patients and population controls. Cancer Epidemiol Biomarkers Prev 1998, 7:875-883.
13. Seow A., Zhao B., Poh W.T., Teh M., Eng P., Wang Y.T., et al. NAT2 slow acetylator genotype is associated with increased risk of lung cancer among non-smoking Chinese women in Singapore. Carcinogenesis 1999, 20:1877-1881.
14. Hou S.M., Ryberg D., Falt S., Deverill A., Tefre T., Borresen A.L., et al. GSTM1 and NAT2 polymorphisms in operable and non-operable lung cancer patients. Carcinogenesis 2000, 21:49-54.
15. Saarikoski S.T., Reinikainen M., Anttila S., Karjalainen A., Vainio H., Husgafvel-Pursiainen K., et al. Role of NAT2 deficiency in susceptibility to lung cancer among asbestos-exposed individuals. Pharmacogenetics 2000, 10:183-185.
16. Zhou W., Liu G., Thurston S.W., Xu L.L., Miller D.P., Wain J.C., et al. Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer. Cancer Epidemiol Biomarkers Prev 2002, 11:15-21.
17. Belogubova E.V., Kuligina E., Togo A.V., Karpova M.B., Ulibina J.M., Shutkin V.A., et al. 'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility. Cancer Lett 2005, 221:177-183.
18. Chiou H.L., Wu M.F., Chien W.P., Cheng Y.W., Wong R.H., Chen C.Y., et al. NAT2 fast acetylator genotype is associated with an increased risk of lung cancer among never-smoking women in Taiwan. Cancer Lett 2005, 223:93-101.
19. Habalova V., Salagovic J., Kalina I., Stubna J. A pilot study testing the genetic polymorphism of N-acetyltransferase 2 as a risk factor in lung cancer. Neoplasma 2005, 52:364-368.
20. Skuladottir H., Autrup H., Autrup J., Tjoenneland A., Overvad K., Ryberg D., et al. Polymorphisms in genes involved in xenobiotic metabolism and lung cancer risk under the age of 60 years. A pooled study of lung cancer patients in Denmark and Norway. Lung Cancer 2005, 48:187-199.
21. Sorensen M., Autrup H., Tjonneland A., Overvad K., Raaschou-Nielsen O. Genetic polymorphisms in CYP1B1, GSTA1 NQO1 and NAT2 and the risk of lung cancer. Cancer Lett 2005, 221:185-190.
22. Borlak J., Reamon-Buettner S.M. N-acetyltransferase 2 (NAT2) gene polymorphisms in colon and lung cancer patients. BMC Med Genet 2006, 7:58.
23. Chen H.C., Cao Y.F., Hu W.X., Liu X.F., Liu Q.X., Zhang J., et al. Genetic polymorphisms of phase II metabolic enzymes and lung cancer susceptibility in a population of Central South China. Dis Markers 2006, 22:141-152.
24. Lee C.N., Yu M.C., Bai K.J., Chang J.H., Fang C.L., Hsu H.L., et al. NAT2 fast acetylator genotypes are associated with an increased risk for lung cancer with wildtype epidermal growth factor receptors in Taiwan. Lung Cancer 2009, 64:9-12.
25. Zupa A., Sgambato A., Bianchino G., Improta G., Grieco V., L.A.T G., et al. GSTM1 and NAT2 polymorphisms and colon, lung and bladder cancer risk: a case-control study. Anticancer Res 2009, 29:1709-1714.
26. Lau J., Ioannidis J.P., Schmid C.H. Quantitative synthesis in systematic reviews. Ann Intern Med 1997, 127:820-826.
27. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
28. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748.
29. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
30. Hein D.W., Doll M.A., Fretland A.J., Leff M.A., Webb S.J., Xiao G.H., et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000, 9:29-42.
31. Hein D.W. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002, 506-507:65-77.
32. Vatsis K.P., Martell K.J., Weber W.W. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci U S A 1991, 88:6333-6337.